Identifying CLL Patients at High Risk of Infection on Treatment Using Machine Learning

伊布替尼 医学 内科学 不利影响 慢性淋巴细胞白血病 肿瘤科 重症监护医学 白血病
作者
Mehdi Parviz,Rudi Agius,Emelie Curovic Rotbain,Kathrine Aarup,Noomi Vainer,Carsten U. Niemann
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 7034-7035
标识
DOI:10.1182/blood-2022-158505
摘要

Background. Targeted therapies, including BTK inhibitors like ibrutinib, have transformed the treatment of patients with chronic lymphocytic leukemia (CLL), improving overall survival and progression-free survival, in particular for patients with the most aggressive CLL disease. However, due to relapse after stopping treatment and the rarity of reaching undetectable minimum residual disease, treatment with ibrutinib requires long-term maintenance therapy. Thus, adverse events (AEs) may have a great impact on the patient's quality of life and overall survival. Several studies have reported higher risk of AEs including severe infections, bleeding, and cardiac events like atrial fibrillation (AF) and hypertension in CLL patients treated with ibrutinib. Identifying patients that might be at a higher risk of developing AEs at the time of treatment initiation could inform individualized treatment and may reduce morbidity and mortality. In this study, we used Machine learning (ML) to predict the risk of developing severe infection (≥ grade 3) after treatment with ibrutinib and/or other standard treatment regimens. Methods. The dataset consisted of 647 patients with CLL that were treated prior to December 2020. Using the Danish CLL registry, the Persimune data warehouse, and Electronic Health Record (EHR) data sources, we extracted baseline features such as age (at the diagnosis and treatment), sex, body mass index (BMI), smoking status, and a range of medical features (with cut-off date set as the date of treatment initiation) including routine laboratory tests, microbiology cultures, known CLL prognostics and historical data on previous infections and type of treatments. The treatment data and AEs were collected by manual review of EHRs as well as through direct data extraction. Features with more than 80% missing values were discarded. For continuous features, missing values were imputed by the mean value of each feature estimated from the training set. Overall, 167 features were used in the modeling. Since some patients received multiple lines of treatment, the dataset consisted of 1400 events of patients receiving treatment. Using an ML algorithm (XGBoost), Cox regression analyses were performed to predict severe infections (≥ Grade 3). Stratified group cross-validation was used to preserve the proportion of samples with severe infection across splits. The contribution of each feature across the study was measured using SHapley Additive exPlanations (SHAP). Results. We identified a high-risk and a low-risk group with 57% and 28% estimated risk of a severe infection within one year of treatment initiation, respectively (Figure 1). The median survival times for the high-risk and low-risk group were 7 (CI%95: 5.0-12.4) and 44 (CI%95: 39.0-56.2) months, respectively. The model could also discriminate the risk of infection within the group of ibrutinib treated and non-ibrutinib treated patients. A c-index of 0.687 (CI%95: 0.649-0.725) for all treatments, 0.672 (CI%95: 0.647-0.696) for ibrutinib, and 0.659 (CI%95: 0.597-0.721) for other treatments (including all treatments except ibrutinib) were achieved using 4-fold cross-validation. To assess impact of different features on the risk of severe treatment related infection, we performed SHAP analysis of feature contribution (Figure 2). The results showed that the targeted therapy (Targeted treatment) and ibrutinib treatment correlated with increased risk of infection. This may in part reflect that targeted therapy was primarily used for patients with aggressive CLL (TP53 aberration and/or relapsed/refractory CLL). In addition, the number of blood cultures drawn prior to treatment correlated with the risk of severe infection. Furthermore, several routine laboratory tests measuring immunoglobulin G, c-reactive protein, and high-density lipoprotein levels were predictive of severe infection. Conclusion. This study confirms the advantage of an ML based approach to stratify patients with CLL prior to initiation of treatment for risk of severe infections within and across treatment regimens. As infections are the main cause of death in CLL, this represents the first steps towards individualized therapy based on risk of AEs. Future work will focus on predicting cardiac events including AF. Validation of the findings in clinical trial populations and other real world data cohorts are awaited before clinical implementation. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage的应助被科研通管家采纳,获得10
刚刚
orixero的应助被科研通管家采纳,获得10
刚刚
无花果的应助被科研通管家采纳,获得10
刚刚
刚刚
刚刚
刚刚
zp的应助被科研通管家采纳,获得20
刚刚
FashionBoy的应助被科研通管家采纳,获得10
刚刚
1秒前
minting完成签到 ,获得积分10
1秒前
3秒前
3秒前
3秒前
3秒前
茉莉花发布了新的文献求助30
4秒前
carol7298发布了新的文献求助10
4秒前
fantasy的应助被小祝没吃饱采纳,获得10
6秒前
6秒前
Dyying发布了新的文献求助10
6秒前
经十路以东的应助被MMLi采纳,获得10
6秒前
7秒前
Chllerye发布了新的文献求助10
7秒前
7秒前
cdercder的应助被云隐采纳,获得10
8秒前
jxc完成签到,获得积分10
8秒前
gxy发布了新的文献求助10
8秒前
8秒前
旺仔发发发布了新的文献求助10
8秒前
nl完成签到 ,获得积分10
8秒前
超级灰狼完成签到 ,获得积分10
8秒前
8秒前
Orange的应助被风语村采纳,获得10
8秒前
9秒前
9秒前
9秒前
yyds的应助被阳光的灵竹采纳,获得10
9秒前
XX发布了新的文献求助10
11秒前
zzr完成签到 ,获得积分10
11秒前
小拉卡咪完成签到,获得积分20
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194041
求助须知:如何正确求助?哪些是违规求助? 9579979
关于积分的说明 21868799
捐赠科研通 7793641
什么是DOI,文献DOI怎么找? 3437477
关于科研通互助平台的介绍 2560942
邀请新用户注册赠送积分活动 2484251